TY  - JOUR
PY  - 2017//
TI  - Suicide prevention in schizophrenia: do long-acting injectable antipsychotics (LAIs) have a role?
JO  - CNS and neurological disorders drug targets
A1  - Pompili, Maurizio
A1  - Orsolini, Laura
A1  - Lamis, Dorian A.
A1  - Goldsmith, David R.
A1  - Nardella, Adele
A1  - Falcone, Giulia
A1  - Corigliano, Valentina
A1  - Luciano, Mario
A1  - Fiorillo, Andrea
SP  - 454
EP  - 462
VL  - 16
IS  - 4
N2  - Suicide risk is a major cause of death among patients with schizophrenia. Death by suicide has been reported in approximately 5% of schizophrenia patients although such figure appears an underestimation of the problem. A number of risk factors are routinely reported as associated with suicide risk among these patients, some of which are modifiable by targeted therapeutic strategies. Clozapine is the only compound that gathered evidence as an effective treatment for reducing suicide risk in schizophrenia. Long-Acting Injectable Antipsychotics (LAIs) have a range of advantages in terms of efficacy, safety and tolerability in the treatment of schizophrenia, and one area of interest is whether LAI-treatment may decrease suicidality by indirectly acting on a range of risk factors for suicide specific to schizophrenia patients. This background encouraged the present, review of research pertaining to LAI in relation to modifiable risk factors for suicide in schizophrenia. We viewed our task as gathering, speculatingand critically appraising the available research relevant to the topic, with the aim of formulating a hypothesis to be tested with further research.<br><br>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.<p />  <p>Language: en</p>
LA  - en
SN  - 1871-5273
UR  - http://dx.doi.org/10.2174/1871527316666170223163629
ID  - ref1
ER  -